Cell Therapy for Lower Limb Ulcers in Patients With Critical Limb Ischemia

Peripheral Arterial Disease Clinical Trial

Official title:

Randomized, Prospective, Controlled, Single-center, Open-label Phase II Clinical Trial Aimed at Evaluating the Safety and Efficacy of Autologous Mesenchymal Stem Cell Therapy for Lower Limb Ulcers in Patients With Critical Limb Ischemia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06326203
• Other study ID #: UPECLIN-MB-8
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: July 1, 2024
• Est. completion date: December 31, 2027

Study information

• Verified date: April 2024
• Source: UPECLIN HC FM Botucatu Unesp
• Contact: Matheus Bertanha, Ph.D.
• Phone: +55(14)3880-1444
• Email: matheus.bertanha[@]unesp.br
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Peripheral arterial disease (PAD) can progress to critical limb ischemia (CLI) of the affected lower limb, characterized by pain at rest, ulcerations or gangrene, with a high risk of amputation. In this phase, the best treatment is arterial limb revascularization, but this is not always possible or even effective for promoting pain relief, healing of ulcers or preventing amputations, in addition to the high socioeconomic cost caused by the disease. Recent advances in cell therapy represent a promising supporting alternative for the treatment of PAD in cases where conventional alternatives have run out. Objective: To evaluate the safety and efficacy of cell therapy with expanded autologous mesenchymal stem cells in the treatment of patients with PAD with CLI and chronic arterial ulcers. Methods: An open randomized clinical study will be performed with 2 groups of 20 patients with CLI: in group 1, a fragment of abdominal fat tissue (10g) will be collected to obtain mesenchymal stem cells, which will be expanded and applied using subcutaneous perilesional injection in the affected lower limb, in addition to the application in the form of a personalized curative biological on the wounds. Group 2 will receive conventional treatment with a Hydrogel dressing with essential fatty acids. Periodic clinical evaluations, complementary exams and photographic record will be carried out. The main outcome of effectiveness will be partial or total wound healing. Safety outcomes will be monitored for infections, gangrene, amputations and deaths. Participants will be monitored for 120 days. Major amputation cases will not be included. An independent external evaluator and blind to the groups will evaluate the results. It is an innovative procedure with high impact and financial return for SUS, in view of the high prevalence of the disease and the high socioeconomic impact of the disease when it progresses to limb amputation.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: December 31, 2027
• Est. primary completion date: July 1, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Absence of distal pulses in the leg (anterior tibial and posterior tibial) and presence or absence of popliteal pulse.
• Peripheral Arterial Disease (PAD).
• Having foot or leg ulcer(s) (distal third) with a minimum area of 1cm2 and a maximum of 3 ulcers totaling up to 20cm2 in the lower limb.
• Having previously received conventional dressing treatment for ulcer indicating no improvement over a minimum period of 3 weeks (antibiotic therapy - if necessary - local care such as mechanical, surgical or chemical debridements - if necessary, dressings).
• PAD with IC classified as Fontaine IV and Rutherford 5.
• Having Ankle Brachial Index (ABI) <0.9 in infragenicular arteries (anterior tibial, posterior tibial, and fibular) or ABI>1.3 in one or more infragenicular arteries when suffering from chronic DMT2 (disease duration > 5 years) not subjected to revascularization treatment or subjected to partial revascularization treatment or treatment failure (stenosis or occlusion) in the last 12 months.
• Inability to revascularize the affected limb (do not have visible infragenicular arteries for surgical approach) and or incomplete revascularization of this limb (undergone endovascular and or surgical treatment that was not able to restore infragenicular pulses) and defined by the doctor that the best available treatment from the surgical vascular point of view has already been performed and was not successful in promoting ulcer healing.
• Drug treatment for PAD and for comorbidities.
• Availability to attend medical appointments.

Exclusion criteria:

• Being pregnant or in the puerperium.
• Having a healed ulcer during the screening period.
• Having signs of systemic infection or active infection in the arterial ulcer or infection of surgical prostheses (bypass, pins, screws). They may be eligible again if they have been successfully treated with antibiotics and the infectious focus has been removed.
• Having an ulcer with devitalized tissue (necrosis). They may be eligible again if they have undergone successful surgical debridement or minor amputations (amputation of toes or limited to the forefoot).
• Having neoplasia and/or being in chemotherapy or radiotherapy treatment or in remission for less than 6 months.
• Being on colchicine or immunomodulators.
• Having infectious diseases such as Human Immunodeficiency Virus (HIV), Hepatitis B and C viruses, Human T-cell Lymphotropic Virus (HTLV); due to the risk of contagion during the manipulation of biological material in the laboratory.
• Having undergone amputation at the level of the leg or thigh in the limb intended to be studied.
• Having COVID-19, diagnosed less than 4 weeks ago.

Related Conditions & MeSH terms

• Chronic Limb-Threatening Ischemia
• Ischemia
• Leg Ulcer
• Peripheral Arterial Disease
• Peripheral Vascular Diseases
• Ulcer

Intervention

Biological:
• CELULAS TRONCO
Cellular Therapy Treatment: The treatment will consist of **20 participants (n=20) who will receive treatment with expanded mesenchymal stem cells (MSCs). The patient will undergo a surgical debridement procedure for the ulcer to be in its optimal condition (Visit 1). Subsequently, the patient will receive MSC application via perilesional injections and a biocovering produced by the study team, also containing the same cells (single session - the MSC-containing dressing will remain in contact with the ulcer for 7 days). After removal of the biological dressing, the ulcer will receive local care with a topical hydrogel dressing, dry gauze, and a crepe bandage, with a minimum of one change per day.

Device:
• CONVENTIONAL DRESSING
The control group will consist of 20 participants (n=20) who will receive local care for the ulcer. The patient will undergo a surgical debridement procedure for the ulcer to be in its optimal condition (Visit 1). Subsequently, the patient will receive the application of a conventional dressing with Hydrogel, dry gauze, and a crepe bandage. The patient will be instructed to change the dressing at least once a day.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
UPECLIN HC FM Botucatu Unesp	Conselho Nacional de Desenvolvimento Científico e Tecnológico

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Major Amputation	Defined by total number of patients subjected to amputation at the knee or tight level.	120 days
Primary	Ulcer Healing	Defined by total or partial epithelization of the ulcer as measured in total square centimeters.	7, 30, 60, 90 and 120 days